TY - JOUR
T1 - Pre- and Intraoperative Visualization of GRPR-Expressing Solid Tumors
T2 - Preclinical Profiling of Novel Dual-Modality Probes for Nuclear and Fluorescence Imaging
AU - Verhoeven, Marjolein
AU - Handula, Maryana
AU - van den Brink, Lilian
AU - de Ridder, Corrina M A
AU - Stuurman, Debra C
AU - Seimbille, Yann
AU - Dalm, Simone U
N1 - Funding Information:
This research was funded by the Dutch Cancer Society (KWF; grant number 11671).
Publisher Copyright:
© 2023 by the authors.
PY - 2023/4/5
Y1 - 2023/4/5
N2 - Image-guided surgery using a gastrin-releasing peptide receptor (GRPR)-targeting dual-modality probe could improve the accuracy of the resection of various solid tumors. The aim of this study was to further characterize our four previously developed GRPR-targeting dual-modality probes that vary in linker structures and were labeled with indium-111 and sulfo-cyanine 5. Cell uptake studies with GRPR-positive PC-3 cells and GRPR-negative NCI-H69 cells confirmed receptor specificity. Imaging and biodistribution studies at 4 and 24 h with 20 MBq/1 nmol [
111In]In-
12-
15 were performed in nude mice bearing a PC-3 and NCI-H69 xenograft, and showed that the probe with only a
pADA linker in the backbone had the highest tumor-to-organ ratios (T/O) at 24 h after injection (T/O > 5 for, e.g., prostate, muscle and blood). For this probe, a dose optimization study with three doses (0.75, 1.25 and 1.75 nmol; 20 MBq) revealed that the maximum image contrast was achieved with the lowest dose. Subsequently, the probe was successfully used for tumor excision in a simulated image-guided surgery setting. Moreover, it demonstrated binding to tissue sections of human prostate, breast and gastro-intestinal stromal tumors. In summary, our findings demonstrate that the developed dual-modality probe has the potential to aid in the complete surgical removal of GRPR-positive tumors.
AB - Image-guided surgery using a gastrin-releasing peptide receptor (GRPR)-targeting dual-modality probe could improve the accuracy of the resection of various solid tumors. The aim of this study was to further characterize our four previously developed GRPR-targeting dual-modality probes that vary in linker structures and were labeled with indium-111 and sulfo-cyanine 5. Cell uptake studies with GRPR-positive PC-3 cells and GRPR-negative NCI-H69 cells confirmed receptor specificity. Imaging and biodistribution studies at 4 and 24 h with 20 MBq/1 nmol [
111In]In-
12-
15 were performed in nude mice bearing a PC-3 and NCI-H69 xenograft, and showed that the probe with only a
pADA linker in the backbone had the highest tumor-to-organ ratios (T/O) at 24 h after injection (T/O > 5 for, e.g., prostate, muscle and blood). For this probe, a dose optimization study with three doses (0.75, 1.25 and 1.75 nmol; 20 MBq) revealed that the maximum image contrast was achieved with the lowest dose. Subsequently, the probe was successfully used for tumor excision in a simulated image-guided surgery setting. Moreover, it demonstrated binding to tissue sections of human prostate, breast and gastro-intestinal stromal tumors. In summary, our findings demonstrate that the developed dual-modality probe has the potential to aid in the complete surgical removal of GRPR-positive tumors.
UR - http://www.scopus.com/inward/record.url?scp=85152905446&partnerID=8YFLogxK
U2 - 10.3390/cancers15072161
DO - 10.3390/cancers15072161
M3 - Article
C2 - 37046825
SN - 2072-6694
VL - 15
JO - Cancers
JF - Cancers
IS - 7
M1 - 2161
ER -